<DOC>
	<DOC>NCT00191516</DOC>
	<brief_summary>A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on quality of sleep in children (aged 6 through 11 years) with Attention-Deficit/Hyperactivity Disorder treated as outpatients in Germany. An 8-week treatment phase is followed by a 16-week extension period.</brief_summary>
	<brief_title>An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Male or female outpatients who are at least 6 years of age and who will not have reached their 12th birthday Diagnosis of ADHD Normal intelligence Weigh less than 20 kg or more than 60 kg at study entry Other relevant psychiatric diagnoses Are at serious suicidal risk as determined by the investigator Have a history of severe allergies Alcohol or drug abuse within the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>